Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer

• Published in: Journal of clinical epidemiology 2015-07, Vol.68 (7), p.833-842
• Main Authors: Ciani, Oriana, Buyse, Marc, Garside, Ruth, Peters, Jaime, Saad, Everardo D, Stein, Ken, Taylor, Rod S
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor - analysis; Biomedical Technology - methods; Biomedical Technology - statistics & numerical data; Cancer therapies; Chemotherapy; Clinical trials; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - chemistry; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - mortality; Colorectal Neoplasms - therapy; Confidence intervals; Deaths; Disease Progression; Disease-Free Survival; Drug therapy; Epidemiology; Health technology assessment; Humans; Internal Medicine; Meta-analysis; Metastasis; Mortality; PFS; Randomized Controlled Trials as Topic; Response rates; Surrogate outcome; Survival Rate; Treatment Outcome; TTP; Tumor response
• ISSN: 0895-4356; 1878-5921
• DOI: 10.1016/j.jclinepi.2015.02.016

Abstract Objectives To quantify and compare the treatment effects on three surrogate end points, progression-free survival (PFS), time to progression (TTP), and tumor response rate (TR) vs. overall survival (OS) based on a meta-analysis of randomized controlled trials (RCTs) of drug interventions in advanced colorectal cancer (aCRC). Study Design and Setting We systematically searched for RCTs of pharmacologic therapies in aCRC between 2003 and 2013. Trial characteristics, risk of bias, and outcomes were recorded based on a predefined form. Univariate and multivariate random-effects meta-analyses were used to estimate pooled summary treatment effects. The ratio of hazard ratios (HRs)/odds ratios (ORs) and difference in medians were used to quantify the degree of difference in treatment effects on the surrogate end points and OS. Spearman ρ , surrogate threshold effect (STE), and R2 were also estimated across predefined trial-level covariates. Results We included 101 RCTs. In univariate and multivariate meta-analyses, we found larger treatment effects for the surrogates than for OS. Compared with OS, treatment effects were on average 13% higher when HRs were measured and 3% to 45% higher when ORs were considered; differences in median PFS/TTP were higher than on OS by an average of 0.5 month. Spearman ρ ranged from 0.39 to 0.80, mean R2 from 0.06 to 0.65, and STE was 0.8 for HRPFS , 0.64 for HRTTP , or 0.28 for ORTR . The stratified analyses revealed high variability across all strata. Conclusion None of the end points in this study were found to achieve the level of evidence (ie, mean R2trial  > 0.60) that has been set to select high or excellent correlation levels by common surrogate evaluation tools. Previous surrogacy relationships observed between PFS and TTP vs. OS in selected settings may not apply across other classes or lines of therapy.